Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2472 • 2019 ACR/ARP Annual Meeting
The Role of Ultrasound for the Assessment of Psoriatic Arthritis Patients with Fibromyalgia – Interim Analysis
Ari Polachek¹, Victoria Furer ², Mirna Zureik ², Sharon Nevo ², Liran Mendel ², David Levartovsky ³, Jonathan Wollman ⁴, Valerie Aloush ⁵, Mark Berman ⁶, Ilana Kaufman ⁶, Yael Lahat ², Hagit Sarbagil-Maman ⁷, Sara Borok ⁶, Adi Broyde ⁶, Lihi Eder ⁸, Daphna Paran ¹ and Ori Elkayam ⁹, ¹Tel-Aviv Sourasky medical center, Tel Aviv, Israel, ²Sourasky Medical Center, Tel-Aviv, Israel, ³Sourasky medical center, Tel Aviv, Israel, ⁴Sourasky Medical Center, Herzelia, Israel, ⁵Tel Aviv Sourasky medical center, Tel Aviv, ⁶Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Tel-Aviv Sourasky medical center, Qiryat-Ono, Israel, ⁸Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ⁹Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel
Background/Purpose: Psoriatic arthritis is a chronic inflammatory disease. More than 20% of patients with PsA patients suffer from fibromyalgia, a chronic pain syndrome characterized by…
Abstract Number: 2492 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Disease-Modifying Drugs in Psoriatic Arthritis (PsA): A Systematic Literature Review
Andreas Kerschbaumer¹, Josef Smolen ¹, Maxime Dougados ², Maarten de Wit ³, Jette Primdahl ⁴, Iain McInnes ⁵, Désirée van der Heijde ⁶, Louise Falzon ⁷, Xenofon Baraliakos ⁸ and Laure Gossec ⁹, ¹Medical University of Vienna, Vienna, Austria, ²Cochin Hospital, Paris, France, ³Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁴Dansk Gigthospital, Sønderborg, Denmark, ⁵Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Northwell Health, New York, ⁸Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: There is now an increasing range of drug options in PsA. To inform the update of the EULAR PsA management recommendations (Ref 1), we…
Abstract Number: 2713 • 2019 ACR/ARP Annual Meeting
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis
Dax Rumsey¹, Aimee Lougee ², Roland Matsouaka ², David Collier ³, Laura Schanberg ⁴, Jennifer Schenfeld ⁵, Natalie Shiff ⁶, Matthew Stoll ⁷, Scott Stryker ³, Pamela F. Weiss ⁸ and Timothy Beukelman ⁹, ¹University of Alberta, Edmonton, AB, Canada, ²Duke University, Durham, NC, ³Amgen Inc., Thousand Oaks, CA, ⁴Duke University Medical Center, Durham, NC, ⁵Amgen, Inc, Thousand Oaks, CA, ⁶University of Florida, Gainesville, FL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹University of Alabama Birmingham, Birmingham, AL
Background/Purpose: Herein we describe characteristics of children with juvenile spondyloarthritis (JSpA, i.e. enthesitis-related arthritis [ERA] or juvenile psoriatic arthritis [JPsA]) enrolled in the Childhood Arthritis…
Abstract Number: 426 • 2019 ACR/ARP Annual Meeting
Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo
Dafna Gladman¹, Laura Coates ², Joseph Wu ³, Lara Fallon ⁴, Ming-Ann Hsu ⁵, Andrew Bushmakin ³, Elizabeth Bacci ⁶, Joseph Cappelleri ³ and Philip Helliwell ⁷, ¹University of Toronto, Toronto, ON, Canada, ²University of Oxford, Oxford, United Kingdom, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Montreal, QC, Canada, ⁵Pfizer Inc, Collegeville, PA, ⁶Evidera, Seattle, WA, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: With many disease domains affected in PsA, clinical and patient-reported outcome (PRO) measures are important to assess disease improvement following treatment. Rapid, meaningful improvements…
Abstract Number: 1081 • 2019 ACR/ARP Annual Meeting
Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Alexis Ogdie¹, Mei Liu ², Sabrina Rebello ², Angel Cronin ², Blessing Dube ², Robert McLean ², Esther Yi ³, Peter Hur ³ and Philip Mease ⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) share many clinical features but are differentiated by key clinical and molecular characteristics. Patients…
Abstract Number: 1479 • 2019 ACR/ARP Annual Meeting
Multi-Symptom Impact on the EQ5D Index in Bio-naïve Active Psoriatic Arthritis Patients: An Analysis Through Week 24 of the GO-VIBRANT Study
Alexis Ogdie¹, Nan Li ², Steve Peterson ², Chetan Karyekar ², Soumya Chakravarty ³, Shelly Kafka ⁴ and Jessica Walsh ⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Janssen Global Services, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by peripheral arthritis, axial inflammation, dactylitis, enthesitis and skin and nail psoriasis. The impact of…
Abstract Number: 1525 • 2019 ACR/ARP Annual Meeting
Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial
Christopher Ritchlin ¹, Vibeke Strand ², Rocco Ballerini ³, Richard C. Chou ⁴, Stephen Rozzo ³, Alan Mendelsohn³ and Arthur Kavanaugh ⁵, ¹Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ²Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA, Palo Alto, CA, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁵University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Tildrakizumab (TIL) is an anti–interleukin-23p19 monoclonal antibody approved by the FDA for treatment of moderate-to-severe plaque psoriasis1,2 and is under investigation for treatment of…
Abstract Number: 1912 • 2019 ACR/ARP Annual Meeting
High Dimensional Flowcytometric Profiling Distinguishes Psoriasis and Psoriatic Arthritis
Michelle Mulder¹, Juul van den Reek ², Elke de Jong ², Bram van Cranenbroek ², Ruben Smeets ², Irma Joosten ², Xuehui He ³, Frank van den Hoogen ¹, Hans Koenen ³ and Mark Wenink ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Radboudumc, Nijmegen, Netherlands, ³Radboudumc, Njimegen, Netherlands
Background/Purpose: Psoriasis (Pso) is a common chronic inflammatory skin disease. About 30% of Pso patients develop psoriatic arthritis (PsA), a chronic inflammation of joints and…
Abstract Number: 2452 • 2019 ACR/ARP Annual Meeting
The Performance of a Multi-marker Genetic Test to Identify Patients with Psoriatic Arthritis Among Psoriasis Patients
Lihi Eder¹, Quan Li ², Dana Jerome ³, Chandra Farrer ⁴, Proton Rahman ⁵ and Tanya N. Burry ⁶, ¹Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, ³University of Toronto, Toronto, ⁴University of Toronto, Toronto, Canada, ⁵Memorial University, Newfoundland, NL, Canada, ⁶Memorial University, St. Johns, Canada
Background/Purpose: Improved understanding of the complex genetic architecture of PsA along with the reduction in the cost of genetic testing provide an opportunity to assess…
Abstract Number: 2473 • 2019 ACR/ARP Annual Meeting
Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?
Michelle Mulder¹, Alfons den Broeder ¹, Berbke van Ginneken ¹, Elien Mahler ¹, Frank van den Hoogen ¹, Johanna Vriezekolk ¹ and Mark Wenink ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease, with involvement of at least five health domains: peripheral joint disease, enthesitis, dactylitis, axial involvement, and skin…
Abstract Number: 2493 • 2019 ACR/ARP Annual Meeting
IL-6 and TNF-α Influence on Clinical Manifestations, Activity and Comorbidity in Psoriatic Arthritis Patients
Maria Elisa Acosta¹, Luis Gomez-Lechon ¹, Guadalupe Manzano Canabal ¹, Olga Compan ², Cristina Hidalgo ³, Olga Martinez ¹, Ana Turrión ¹, Javier del Pino ¹ and Carlos Montilla ¹, ¹Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²Hospital Clinico Universitario de Salamanca, SALAMANCA, Spain, ³Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain
Background/Purpose: The activation of the Th-1 and Th-17 lymphocytes response seems to be one of the causes associated with PsA onset. During this process cytokines…
Abstract Number: 2717 • 2019 ACR/ARP Annual Meeting
Long-term Outcome of Juvenile-onset Psoriatic Arthritis
Devy Zisman¹, Tal Gazitt ², Amir Haddad ², Idit Lavi ², Snezana Barac ³, Vinod Chandran ⁴, Jan Dutz ⁵, Lihi Eder ⁶, James T Elder ⁷, Richard Hayday ⁸, Proton Rahman ⁹, Christopher Ritchlin ¹⁰, Sherry Rohekar ¹¹, Cheryl F. Rosen ¹² and Dafna Gladman ¹³, ¹Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, ²Carmel Hospital, Haifa, Israel, ³Winnipeg Clinic, Winnipeg, MB, Canada, ⁴Department of Medicine, University of Toronto,Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of British Columbia, Vancuver, BC, Canada, ⁶Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ⁷University of Michigan Medical School,, Ann Arbor, MI, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Memorial University, Newfoundland, NL, Canada, ¹⁰Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ¹¹Western University, London, ON, Canada, ¹²Division of Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: There is no consensus in the literature with regard to the features and long-term prognosis of psoriatic arthritis (PsA) starting in childhood (jPsA). We…
Abstract Number: 436 • 2019 ACR/ARP Annual Meeting
Poor Concordance Between Remission Judged by Physicians and a Patient-Acceptable Symptom State in Psoriatic Arthritis
Rubén Queiro¹, Estefania Pardo ¹, Lilyan Charca ¹, Sara Alonso ¹, L. Arboleya ² and Mercedes Alperi-López ¹, ¹Hospital Universitario Central de Asturias, Oviedo, Spain, ²Hospital Central Asturias, OViedo
Background/Purpose: Both the evaluation of disease activity in psoriatic arthritis (PsA) and the determination of the impact of the disease on patients' lives are subjects…
Abstract Number: 1085 • 2019 ACR/ARP Annual Meeting
Probiotic Use and Psoriatic Arthritis Disease Activity
Madison Grinnell¹, Kristin Wipfler ², Alexis Ogdie ³ and Kaleb Michaud ⁴, ¹University of Nebraska College of Medicine, OMAHA, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Probiotics have been hypothesized to mediate inflammation through gut microbiome modulation, and growing evidence has suggested that our intestinal gut microbiome may play a…
Abstract Number: 1481 • 2019 ACR/ARP Annual Meeting
Real-World Use of Apremilast in Combination with Biologic Therapy in Patients with Psoriatic Arthritis: Findings from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Mei Liu ², Meghan Glynn ³, Kelechi Emeanuru ², Leslie Harrold ⁴, Sven Richter ⁵, Benoit Guerette ⁵ and Philip Mease ⁶, ¹Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴Corrona, LLC and University of Massachusetts Medical School, Worcester, MA, ⁵Celgene Corporation, Summit, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in adult patients with active PsA despite prior use of csDMARDs and/or biologics in phase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].